SynCardia Systems has been awarded its first patent in China for the Emperor Next-Generation Total Artificial Heart.

TUCSON, Ariz., Jan. 9, 2025 /PRNewswire/ -- SynCardia Systems, LLC ("SynCardia" or the "Company"), a subsidiary of Picard Medical, Inc. and a frontrunner in total artificial heart innovations, is excited to share that the China National Intellectual Property Administration ("CNIPA") has officially informed the Company of its decision to award SynCardia its inaugural patent for the next-generation total artificial heart. This patent outlines groundbreaking technology designed to remove external drive mechanisms by completely embedding the pumping function within the implanted artificial heart ventricle.

This achievement marks a crucial advancement in SynCardia's goal of developing a completely implantable total artificial heart, known as the "Emperor." This device aims to offer a life-saving alternative for patients facing severe heart failure globally. The latest iteration of the Emperor artificial heart enhances SynCardia's established total artificial heart technology, incorporating new features designed to improve patient recovery and broaden access to essential cardiac support.

"We are excited to get this news from CNIPA, as it underscores the worldwide significance of our goal to enhance our artificial heart technology," stated Patrick NJ Schnegelsberg, CEO of SynCardia Systems. "This patent plays a vital role in our plan to deliver the SynCardia Total Artificial Heart and the upcoming Emperor artificial heart to patients in China."

SynCardia is dedicated to leading innovations in its artificial heart technology and broadening its market presence. The company actively collaborates with global regulatory authorities and partners to guarantee that both its existing and next-generation total artificial heart will be accessible to patients around the globe in the future.

Information on SynCardia Systems, LLC

SynCardia Systems, LLC stands at the forefront of total artificial heart innovation. The company offers the SynCardia Total Artificial Heart ("STAH"), which holds the distinction of being the sole artificial heart approved by both the U.S. Food and Drug Administration and Health Canada. To date, the STAH has been successfully implemented in more than 2,100 patients around the globe.

Statements Regarding Future Expectations

This press release contains statements that are "forward-looking statements" within the meaning of the Pr